These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 23222783)

  • 1. Setting the stage for biosimilar monoclonal antibodies.
    Schneider CK; Vleminckx C; Gravanis I; Ehmann F; Trouvin JH; Weise M; Thirstrup S
    Nat Biotechnol; 2012 Dec; 30(12):1179-85. PubMed ID: 23222783
    [No Abstract]   [Full Text] [Related]  

  • 2. Japanese regulation of biosimilar products: past experience and current challenges.
    Arato T
    Br J Clin Pharmacol; 2016 Jul; 82(1):30-40. PubMed ID: 26987746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biopharmaceutical benchmarks 2018.
    Walsh G
    Nat Biotechnol; 2018 Dec; 36(12):1136-1145. PubMed ID: 30520869
    [No Abstract]   [Full Text] [Related]  

  • 4. Interchangeability, immunogenicity and biosimilars.
    Ebbers HC; Crow SA; Vulto AG; Schellekens H
    Nat Biotechnol; 2012 Dec; 30(12):1186-90. PubMed ID: 23222784
    [No Abstract]   [Full Text] [Related]  

  • 5. Biosimilar regulation in the EU.
    Kurki P; Ekman N
    Expert Rev Clin Pharmacol; 2015; 8(5):649-59. PubMed ID: 26294076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monoclonal antibody: the corner stone of modern biotherapeutics.
    Xia ZN; Cai XT; Cao P
    Yao Xue Xue Bao; 2012 Oct; 47(10):1275-80. PubMed ID: 23289138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Biosimilars: regulatory status for approval].
    Herrero Ambrosio A
    Farm Hosp; 2010 Mar; 34 Suppl 1():16-8. PubMed ID: 20920853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maintaining 'standards' for biosimilar monoclonal antibodies.
    Prior S; Metcalfe C; Hufton SE; Wadhwa M; Schneider CK; Burns C
    Nat Biotechnol; 2021 Mar; 39(3):276-280. PubMed ID: 33664522
    [No Abstract]   [Full Text] [Related]  

  • 9. Regulatory considerations in oncologic biosimilar drug development.
    Macdonald JC; Hartman H; Jacobs IA
    MAbs; 2015; 7(4):653-61. PubMed ID: 25961747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biosimilars: how similar?
    Strand V; Cronstein B
    Intern Med J; 2014 Mar; 44(3):218-23. PubMed ID: 24118772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical trial development for biosimilars.
    Alten R; Cronstein BN
    Semin Arthritis Rheum; 2015 Jun; 44(6 Suppl):S2-8. PubMed ID: 26058550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Biosimilars in inflammatory bowel disease].
    Siegmund B; Atreya R; Bokemeyer B; Kruis W; Mudter J; Sander C; Schreiber S; Reindl W; Zeissig S; Kucharzik T
    Z Gastroenterol; 2016 Nov; 54(11):1217-1222. PubMed ID: 27711946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biosimilar infliximab: an expert view.
    Genazzani A; Altomare G; Balato N; Cusano F; De Pità O; Loconsole F; Micali G; Piaserico S; Girolomoni G
    G Ital Dermatol Venereol; 2015 Aug; 150(4):449-59. PubMed ID: 25747260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Global regulatory standards for the approval of biosimilars.
    Mounho B; Phillips A; Holcombe K; Grampp G; Lubiniecki T; Mollerup I; Jones C
    Food Drug Law J; 2010; 65(4):819-37, ii-iii. PubMed ID: 24479248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biosimilars: The US Regulatory Framework.
    Christl LA; Woodcock J; Kozlowski S
    Annu Rev Med; 2017 Jan; 68():243-254. PubMed ID: 27813877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biosimilars in Dermatology: Current Situation (Part II).
    Puig L; Carretero G; Daudén E; Ferrándiz C; Marrón SE; Martorell A; Pérez-Suárez B; Rodriguez-Cerdeira C; Ruiz-Villaverde R; Sánchez-Carazo JL; Velasco M;
    Actas Dermosifiliogr; 2015 Sep; 106(7):550-4. PubMed ID: 26049964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current Japanese Regulatory Systems for Generics and Biosimilars.
    Kuribayashi R; Sawanobori K
    J Pharm Sci; 2018 Mar; 107(3):785-787. PubMed ID: 29113922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDA approves biosimilar version of infliximab.
    Traynor K
    Am J Health Syst Pharm; 2016 May; 73(10):604-6. PubMed ID: 27147206
    [No Abstract]   [Full Text] [Related]  

  • 19. Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases.
    Braun J; Kudrin A
    Immunotherapy; 2015; 7(2):73-87. PubMed ID: 25713985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-neoplastic biosimilars--the same rules as for cytotoxic generics cannot be applied.
    Mellstedt H
    Ann Oncol; 2013 Sep; 24 Suppl 5():v23-8. PubMed ID: 23975701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.